Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1995/015025external-prioritypatent/WO1996014846A1/en
Application filed by Synaptic Pharma Corp, Merck & Co IncfiledCriticalSynaptic Pharma Corp
Publication of PE30098A1publicationCriticalpatent/PE30098A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
SE REFIERE A LOS ENANTIOMEROS DE LOS DERIVADOS DE DIHIDROPIRIMIDINAS QUE COMPRENDEN: LAS FORMULAS (I) Y (II). ESTOS COMPUESTOS SON ANTAGONISTAS ESPECIFICOS DEL RECEPTOR ALFA 1 C ADRENERGICO, UTILES EN EL TRATAMIENTO DE LA HIPERPLASIA PROSTATICA BENIGNA, ENTRE OTROSREFERS TO THE ENANTIOMEROS OF THE DERIVATIVES OF DIHYDROPYRIMIDINES THAT INCLUDE: FORMULAS (I) AND (II). THESE COMPOUNDS ARE SPECIFIC ANTAGONISTS OF THE ALPHA 1 C ADRENERGIC RECEPTOR, USEFUL IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA, AMONG OTHERS
PE1996000825A1995-11-161996-11-15
DIHYDROPYRIMIDINES AND USES OF THE SAME
PE30098A1
(en)